Skip navigation
Universidade de Brasília
Use este identificador para citar ou linkar para este item: http://repositorio2.unb.br/jspui/handle/10482/48738
Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
ARTIGO_InVitroInVivo.pdf2,42 MBAdobe PDFVisualizar/Abrir
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorZonari, Alessandra-
dc.contributor.authorBrace, Lear E.-
dc.contributor.authorSilva, Thuany Alencar-
dc.contributor.authorPorto, William Farias-
dc.contributor.authorFoyt, Daniel-
dc.contributor.authorGuiang, Mylieneth-
dc.contributor.authorOchoa Cruz, Edgar Andres-
dc.contributor.authorFranco, Octávio Luiz-
dc.contributor.authorOliveira, Carolina R.-
dc.contributor.authorBoroni, Mariana-
dc.contributor.authorCarvalho, Juliana Lott de-
dc.date.accessioned2024-07-11T13:20:19Z-
dc.date.available2024-07-11T13:20:19Z-
dc.date.issued2022-08-05-
dc.identifier.citationZONARI, Alessandra et al. In vitro and in vivo toxicity assessment of the senotherapeutic Peptide 14. Toxicology Reports, [S. l.], v. 9, p. 1632-1638, 2022. DOI: https://doi.org/10.1016/j.toxrep.2022.07.018. Disponível em: https://www.sciencedirect.com/science/article/pii/S221475002200172X?via%3Dihub. Acesso em: 11 jul. 2024.pt_BR
dc.identifier.urihttp://repositorio2.unb.br/jspui/handle/10482/48738-
dc.language.isoengpt_BR
dc.publisherElsevier B.V.pt_BR
dc.rightsAcesso Abertopt_BR
dc.titleIn vitro and in vivo toxicity assessment of the senotherapeutic Peptide 14pt_BR
dc.typeArtigopt_BR
dc.subject.keywordSenescência celularpt_BR
dc.subject.keywordEnvelhecimentopt_BR
dc.subject.keywordPeptídeospt_BR
dc.subject.keywordToxicidadept_BR
dc.rights.license© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.toxrep.2022.07.018pt_BR
dc.description.abstract1Senotherapeutic molecules decrease cellular senescence burden, constituting promising approaches to combat the accumulation of senescent cells observed in chronological aging and age-related diseases. Numerous molecules have displayed senotherapeutic potential, but toxicity has been frequently observed. Recently, a new senotherapeutic compound, Peptide 14, was developed to modulate cellular senescence in the skin. In order to assess the potential toxic and genotoxic effects of the peptide, we observed the viability of human primary dermal fibroblasts and epidermal keratinocytes with Peptide 14 treatment, and show that it is mostly non-toxic in concentrations up to 100 μM. Cancer lines were also used to investigate its potential of modulating proliferation. Different concentrations of the peptide promoted a discrete reduction in the proliferation of cancerous cells of the MeWo and HeLa lineages. In full-thickness human skin equivalents, topically formulated Peptide 14 also failed to exert any significant irritation, nor cellular toxicity when added to the culture media. Genotoxic assays including the Ames, micronucleus, and karyotyping tests also indicate the safety of the peptide. Finally, the irritative potential of the peptide was assessed in human subjects in a repeated insult patch test executed using 1 mM peptide. No visible skin reactions were observed in any of the 54 participants. Taken together, the present data support that Peptide 14 is a senotherapeutic molecule with a positive safety profile as tested with cruelty-free models, justifying further studies involving the peptide.pt_BR
dc.contributor.affiliationOneSkin, Inc., San Francisco, CA 94107, USApt_BR
dc.contributor.affiliationOneSkin, Inc., San Francisco, CA 94107, USApt_BR
dc.contributor.affiliationCatholic University of Brasilia, Genomic Sciences and Biotechnology Programpt_BR
dc.contributor.affiliationOneSkin, Inc., San Francisco, CA 94107, USApt_BR
dc.contributor.affiliationPorto Reports, Brasíliapt_BR
dc.contributor.affiliationOneSkin, Inc., San Francisco, CA 94107, USApt_BR
dc.contributor.affiliationOneSkin, Inc., San Francisco, CA 94107, USApt_BR
dc.contributor.affiliationOneSkin, Inc., San Francisco, CA 94107, USApt_BR
dc.contributor.affiliationCatholic University of Brasilia, Genomic Sciences and Biotechnology Programpt_BR
dc.contributor.affiliationCatholic University of Brasilia, Genomic Sciences and Biotechnology Program, Center of Proteomic Analyses and Biochemistrypt_BR
dc.contributor.affiliationCatholic University Dom Bosco, Campo Grande, S-Inova Biotech, Biotechnology Programpt_BR
dc.contributor.affiliationOneSkin, Inc., San Francisco, CA 94107, USApt_BR
dc.contributor.affiliationOneSkin, Inc., San Francisco, CA 94107, USApt_BR
dc.contributor.affiliationBrazilian National Cancer Institute (INCA), Bioinformatics and Computational Biology Labpt_BR
dc.contributor.affiliationCatholic University of Brasilia, Genomic Sciences and Biotechnology Programpt_BR
dc.contributor.affiliationUniversity of Brasília, Faculty of Medicine, Interdisciplinary Biosciences Laboratorypt_BR
dc.description.unidadeFaculdade de Medicina (FM)pt_BR
Aparece nas coleções:Artigos publicados em periódicos e afins

Mostrar registro simples do item Visualizar estatísticas



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.